[Helicobacter pylori eradication therapy in Korea].
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim S.Y. | - |
dc.contributor.author | Jung S.W. | - |
dc.date.available | 2020-11-03T04:46:01Z | - |
dc.date.issued | 2011 | - |
dc.identifier.issn | 1598-9992 | - |
dc.identifier.issn | 2233-6869 | - |
dc.identifier.uri | https://scholarworks.korea.ac.kr/kumedicine/handle/2020.sw.kumedicine/14064 | - |
dc.description.abstract | Helicobacter pylori (H. pylori) is known to be associated with many gastrointestinal diseases including peptic ulcer. In Korea, eradication of H. pylori is recommended for peptic ulcer disease, low grade gastric mucosa-associated lymphoid tissue lymphoma, and early gastric cancer. Standard triple therapy using proton pump inhibitor, clarithromycin, and amoxicillin and bismuth-containing quadruple therapy have been the main first-line and second-line therapy for H. pylori in Korea. Although eradication rate of second-line quadruple therapy remains similar to that of the past, the success rate of eradication with triple therapy has decreased with increasing antimicrobial resistance to H. pylori. There is no standard third-line therapy, and some regimens that incorporate levofloxacin, moxifloxacin, and rifabutin can be used. New regimens such as sequential or concomitant therapy are suggested as alternative treatment for H. pylori. We need more well designed randomized controlled studies to choose proper treatment for H. pylori infection. | - |
dc.format.extent | 7 | - |
dc.language | 한국어 | - |
dc.language.iso | KOR | - |
dc.title | [Helicobacter pylori eradication therapy in Korea]. | - |
dc.type | Article | - |
dc.publisher.location | 대한민국 | - |
dc.identifier.doi | 10.4166/kjg.2011.58.2.67 | - |
dc.identifier.scopusid | 2-s2.0-84555170214 | - |
dc.identifier.bibliographicCitation | The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, v.58, no.2, pp 67 - 73 | - |
dc.citation.title | The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi | - |
dc.citation.volume | 58 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 67 | - |
dc.citation.endPage | 73 | - |
dc.type.docType | Review | - |
dc.identifier.kciid | ART001577756 | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.subject.keywordPlus | amoxicillin | - |
dc.subject.keywordPlus | antiinfective agent | - |
dc.subject.keywordPlus | clarithromycin | - |
dc.subject.keywordPlus | proton pump inhibitor | - |
dc.subject.keywordPlus | drug combination | - |
dc.subject.keywordPlus | Helicobacter infection | - |
dc.subject.keywordPlus | Helicobacter pylori | - |
dc.subject.keywordPlus | human | - |
dc.subject.keywordPlus | marginal zone lymphoma | - |
dc.subject.keywordPlus | peptic ulcer | - |
dc.subject.keywordPlus | review | - |
dc.subject.keywordPlus | South Korea | - |
dc.subject.keywordPlus | stomach tumor | - |
dc.subject.keywordPlus | Amoxicillin | - |
dc.subject.keywordPlus | Anti-Bacterial Agents | - |
dc.subject.keywordPlus | Clarithromycin | - |
dc.subject.keywordPlus | Drug Therapy, Combination | - |
dc.subject.keywordPlus | Helicobacter Infections | - |
dc.subject.keywordPlus | Helicobacter pylori | - |
dc.subject.keywordPlus | Humans | - |
dc.subject.keywordPlus | Lymphoma, B-Cell, Marginal Zone | - |
dc.subject.keywordPlus | Peptic Ulcer | - |
dc.subject.keywordPlus | Proton Pump Inhibitors | - |
dc.subject.keywordPlus | Republic of Korea | - |
dc.subject.keywordPlus | Stomach Neoplasms | - |
dc.subject.keywordAuthor | Helicobacter pylori | - |
dc.subject.keywordAuthor | Drug therapy | - |
dc.subject.keywordAuthor | Combination | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
73, Goryeodae-ro, Seongbuk-gu, Seoul, Republic of Korea (02841)82-2-2286-1265
COPYRIGHT 2020 KOREA UNIVERSITY MEDICAL LIBRARY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.